 Granulocyte-Macrophage Colony-Stimulating Factor
"Granulocyte-Macrophage Colony-Stimulating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
| Descriptor ID |
D016178
|
| MeSH Number(s) |
D12.644.276.374.410.240.375 D12.776.395.240.300 D12.776.467.374.410.240.375 D23.529.374.410.240.375
|
| Concept/Terms |
Granulocyte-Macrophage Colony-Stimulating Factor- Granulocyte-Macrophage Colony-Stimulating Factor
- Granulocyte Macrophage Colony Stimulating Factor
- CSF-2
- Tumor-Cell Human GM Colony-Stimulating Factor
- Tumor Cell Human GM Colony Stimulating Factor
- GM-CSF
- Histamine-Producing Cell-Stimulating Factor
- Cell-Stimulating Factor, Histamine-Producing
- Histamine Producing Cell Stimulating Factor
- TC-GM-CSF
- Colony-Stimulating Factor, Granulocyte-Macrophage
- Colony Stimulating Factor, Granulocyte Macrophage
- CSF-GM
|
Below are MeSH descriptors whose meaning is more general than "Granulocyte-Macrophage Colony-Stimulating Factor".
Below are MeSH descriptors whose meaning is more specific than "Granulocyte-Macrophage Colony-Stimulating Factor".
This graph shows the total number of publications written about "Granulocyte-Macrophage Colony-Stimulating Factor" by people in this website by year, and whether "Granulocyte-Macrophage Colony-Stimulating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 0 | 1 | 1 | | 1989 | 0 | 1 | 1 | | 1990 | 0 | 2 | 2 | | 1991 | 2 | 1 | 3 | | 1992 | 2 | 1 | 3 | | 1993 | 4 | 1 | 5 | | 1994 | 1 | 2 | 3 | | 1995 | 3 | 4 | 7 | | 1996 | 3 | 1 | 4 | | 1997 | 1 | 2 | 3 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 3 | 5 | | 2000 | 2 | 0 | 2 | | 2001 | 0 | 3 | 3 | | 2002 | 2 | 5 | 7 | | 2003 | 3 | 3 | 6 | | 2004 | 0 | 2 | 2 | | 2005 | 2 | 0 | 2 | | 2006 | 1 | 4 | 5 | | 2007 | 1 | 3 | 4 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 3 | 4 | | 2010 | 1 | 2 | 3 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2019 | 2 | 1 | 3 | | 2020 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Granulocyte-Macrophage Colony-Stimulating Factor" by people in Profiles.
-
Faiena I, Comin-Anduix B, Berent-Maoz B, Bot A, Zomorodian N, Sachdeva A, Said J, Cheung-Lau G, Pang J, Macabali M, Chodon T, Wang X, Cabrera P, Kaplan-Lefko P, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282.
-
Piper C, Zhou V, Komorowski R, Szabo A, Vincent B, Serody J, Alegre ML, Edelson BT, Taneja R, Drobyski WR. Pathogenic Bhlhe40+ GM-CSF+ CD4+ T cells promote indirect alloantigen presentation in the GI tract during GVHD. Blood. 2020 02 20; 135(8):568-581.
-
Frid MG, McKeon BA, Thurman JM, Maron BA, Li M, Zhang H, Kumar S, Sullivan T, Laskowsky J, Fini MA, Hu S, Tuder RM, Gandjeva A, Wilkins MR, Rhodes CJ, Ghataorhe P, Leopold JA, Wang RS, Holers VM, Stenmark KR. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Am J Respir Crit Care Med. 2020 01 15; 201(2):224-239.
-
Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502.
-
Denson LA, Jurickova I, Karns R, Shaw KA, Cutler DJ, Okou D, Valencia CA, Dodd A, Mondal K, Aronow BJ, Haberman Y, Linn A, Price A, Bezold R, Lake K, Jackson K, Walters TD, Griffiths A, Baldassano RN, Noe JD, Hyams JS, Crandall WV, Kirschner BS, Heyman MB, Snapper S, Guthery SL, Dubinsky MC, Leleiko NS, Otley AR, Xavier RJ, Stevens C, Daly MJ, Zwick ME, Kugathasan S. Genetic and Transcriptomic Variation Linked to Neutrophil Granulocyte-Macrophage Colony-Stimulating Factor Signaling in Pediatric Crohn's Disease. Inflamm Bowel Dis. 2019 02 21; 25(3):547-560.
-
McDermott MM, Polonsky TS, Guralnik JM, Ferrucci L, Tian L, Zhao L, Stein J, Domanchuk K, Criqui MH, Taylor DA, Li L, Kibbe MR. Racial Differences in the Effect of Granulocyte Macrophage Colony-Stimulating Factor on Improved Walking Distance in Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. J Am Heart Assoc. 2019 01 22; 8(2):e011001.
-
McDermott MM, Ferrucci L, Tian L, Guralnik JM, Lloyd-Jones D, Kibbe MR, Polonsky TS, Domanchuk K, Stein JH, Zhao L, Taylor D, Skelly C, Pearce W, Perlman H, McCarthy W, Li L, Gao Y, Sufit R, Bloomfield CL, Criqui MH. Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. JAMA. 2017 12 05; 318(21):2089-2098.
-
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 07; 18(7):946-957.
-
Jajtner AR, Hoffman JR, Townsend JR, Beyer KS, Varanoske AN, Church DD, Oliveira LP, Herrlinger KA, Radom-Aizik S, Fukuda DH, Stout JR. The effect of polyphenols on cytokine and granulocyte response to resistance exercise. Physiol Rep. 2016 12; 4(24).
-
Luke JJ, Donahue H, Nishino M, Giobbie-Hurder A, Davis M, Bailey N, Ott PA, Hodi FS. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res. 2015 Sep; 3(9):986-91.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|